-

01:56:13 PM

CVAC Stock News

CVAC - CureVac N.V.

08/17/23 7:15 AM

Nasdaq : CVAC

earnings

CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update

Initiated Phase 2 study in COVID-19 with monovalent and bivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSKInitiated Phase 1 study of cancer vaccine candidate, CVGBM, for surgically resected glioblastoma; recruitment of

RHEA-AI

neutral

08/01/23 7:15 AM

Nasdaq : CVAC

clinical trialcovid-19

CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK

Phase 2 study initiated at clinical sites in Australia with monovalent and bivalent mRNA COVID-19 vaccine candidatesVaccine candidates developed in collaboration with GSK within COVID-19 vaccine development programTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 1, 2023 / CureVac N.V.

RHEA-AI

neutral

07/21/23 9:00 AM

Nasdaq : CVAC

Dr. Igor Splawski Appointed as Chief Scientific Officer of Yarrow Biotechnology

Yarrow Biotechnology, Inc., an RTW Investments, LP- incubated company developing nucleic acid therapeutics and other modalities for severe, genetically defined diseases including those of the central nervous system, today announced the appointment of Dr. Igor Splawski as Chief Scientific Officer. Splawski was previously the Chief Scientific Officer and a...

RHEA-AI

neutral

07/14/23 7:15 AM

Nasdaq : CVAC

CureVac Announces Update to the Management Team

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 14, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that Dr. Igor

RHEA-AI

neutral

07/13/23 7:15 AM

Nasdaq : CVAC

CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights

Cases in Germany and the U.S. broadened by asserting additional, new intellectual property rightsThree new intellectual property rights added to infringement lawsuit against Pfizer/BioNTech in Germany, increasing number of asserted intellectual property rights to eightTenth patent added to

RHEA-AI

neutral

06/20/23 7:25 AM

Nasdaq : CVAC

clinical trial

CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

Cancer vaccine candidate CVGBM utilizes single mRNA, encoding eight epitopes of tumor-associated antigens with demonstrated relevance in glioblastomaStudy designed to evaluate safety and immunogenicity in patients with glioblastoma after surgical resection and radiotherapyFirst study to apply

RHEA-AI

neutral

06/20/23 7:10 AM

Nasdaq : CVAC

management

CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 20, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of

RHEA-AI

neutral

06/19/23 1:33 PM

Nasdaq : CVAC

CureVac Announces Voting Results of General Meeting

TÜBINGEN, GERMANY and BOSTON, USA / ACCESSWIRE / June 19, 2023 / CureVac N.V. (Nasdaq:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the voting results of the

RHEA-AI

neutral

05/30/23 7:30 AM

Nasdaq : CVAC

earnings

CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update

Initiated Phase 1/2 study in seasonal flu with multivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSKFiled infringement counterclaim in U.S. patent litigation with Pfizer/BioNTech; case filed under nine CureVac patents;

RHEA-AI

neutral

05/19/23 7:15 AM

Nasdaq : CVAC

CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech

Motion to transfer U.S. litigation to Eastern District of Virginia granted at CureVac's request and expected to significantly accelerate U.S. litigation timelineCureVac is filing counterclaim in U.S. court under nine patents covering foundational mRNA innovations highly relevant to the design,

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

CVAC Data

IndustryPharmaceutical Preparation Manufacturing
Security nameCureVac N.V.
SectorManufacturing
Tags
- Health Technology
- Pharmaceuticals: Major
CountryGermany

About CureVac N.V.

founded in 2000 as a spin-off from the university of tϋbingen in germany, curevac is a leading company in the field of mrna technology and was the first company to start clin-ical trials on mrna-based drugs. the biopharmaceutical company has more than 17 years of expertise in handling and optimizing this versatile molecule for medical purposes. the basic principle of curevac's proprietary technology is the use of mrna as a data car-rier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. the company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies. since its inception, strongly backed by sap founder dietmar hopp’s dievini, curevac has received approximately $420 million (€400 million) in equity investments including an investment of the bill & melinda gates foundation of $ 52million in 2015. curevac has entered into various collaborations with multinational corporations and o